ScreenerHero

VIR Vir Biotechnology, Inc.

NAS · US · Healthcare · Biotechnology · vir.bio
11.52USD-0.69%Mkt Cap: 1.95B $P/E: —

Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical dev…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap1.95B USD
Enterprise Value1.52B USD
Revenue (TTM)303.23M USD
Gross Profit66.49M USD
Net Income (TTM)-437.99M USD
Revenue/Share2.04 USD
Last Price11.52 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees367
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.66
PEG—
EV/EBITDA-5.68
EV/Revenue5.02
P/S6.47
P/B2.00
EPS (TTM)-1.76
EPS (Forward)-2.49
52W Range
4.81594% of range11.94
52W High11.94 USD
52W Low4.815 USD
Profitability
Gross Margin99.96%
Oper. Margin30.75%
EBITDA Margin-88.37%
Profit Margin-658.43%
ROE-57.23%
ROA-43.68%
Growth
Revenue Growth19582.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-391.78M USD
CapEx (TTM)4.83M USD
FCF Margin-12.82%
FCF Yield-1.99%
Net Debt-439.45M USD
Net Debt/EBITDA1.64
Balance Sheet
Debt/Equity0.13
Current Ratio6.04
Quick Ratio5.67
Book Value/Sh5.81 USD
Cash/Share3.15 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)20.78 USD
Upside (mean)+80.4%
Target Range15.00 USD – 30.00 USD
15.00+80.4% to mean30.00
# Analysts9
Ownership
Shares Out.169.22M
Float129.82M
Insiders6.57%
Institutions84.36%
Short Interest
Short Ratio9.7d
Short % Float11.76%
Short % Out.11.62%
Shares Short19.66M
Short (prev mo.)19.60M
Technical
SMA 5010.20 (+13.0%)
SMA 2009.049 (+27.3%)
Beta1.59
S&P 52W Chg16.45%
Avg Vol (30d)2.18M
Avg Vol (10d)1.93M
Technical Indicators
RSI (14)60.3
MACD0.3498
MACD Signal0.3204
MACD Hist.+0.0294
BB Upper11.83 USD
BB Middle11.00 USD
BB Lower10.17 USD
BB Width15.07%
ATR (14)0.5923 USD
Vol Ratio (20d)1.62x